



TYPE 2 DIABETES MELLITUS AS A DETERMINANT OF CARDIOVASCULAR COMPLICATIONS DEVELOPMENT

Nazarova S. K.

Mirzarakhimova N. I.

2nd Issue Department of Public Health and Healthcare Management Tashkent State Medical University

Abstract

Type 2 diabetes mellitus represents a major global public health challenge and is strongly associated with an increased risk of cardiovascular morbidity and mortality. The present study aims to analyze type 2 diabetes mellitus as a key pathogenic factor contributing to the development of cardiovascular complications. The research is based on the analysis of clinical, metabolic, and epidemiological data reflecting the impact of chronic hyperglycemia, insulin resistance, dyslipidemia, and systemic inflammation on the cardiovascular system. Particular attention is given to the mechanisms linking diabetes with atherosclerosis progression, endothelial dysfunction, arterial stiffness, and myocardial structural remodeling. The results indicate that type 2 diabetes mellitus significantly accelerates the development of ischemic heart disease, hypertension, heart failure, and cerebrovascular disorders, even in the absence of overt clinical symptoms at early stages. The findings emphasize that cardiovascular complications often develop subclinically and progress more aggressively in patients with type 2 diabetes. These observations highlight the necessity of early identification of cardiovascular risk factors, comprehensive metabolic control, and integrated preventive strategies aimed at reducing cardiovascular burden in patients with type 2 diabetes mellitus.

Keywords: Type 2 diabetes mellitus; cardiovascular complications; atherosclerosis; endothelial dysfunction; insulin resistance; cardiovascular risk.



Introduction

Type 2 diabetes mellitus has emerged as one of the most prevalent non-communicable diseases worldwide and represents a major contributor to global morbidity and mortality. The progressive increase in its incidence is closely linked to population aging, urbanization, sedentary lifestyles, and dietary changes. Beyond disturbances in glucose metabolism, type 2 diabetes mellitus is increasingly recognized as a systemic metabolic disorder that profoundly affects cardiovascular structure and function, thereby substantially elevating the risk of cardiovascular complications.

Cardiovascular diseases remain the leading cause of death among patients with type 2 diabetes mellitus. Epidemiological evidence indicates that individuals with diabetes have a two- to fourfold higher risk of developing cardiovascular complications compared with non-diabetic populations. Moreover, cardiovascular events in diabetic patients tend to occur earlier, progress more rapidly, and are associated with poorer clinical outcomes. Importantly, cardiovascular pathology in diabetes often develops insidiously, with subclinical changes preceding overt clinical manifestations by several years.

The pathophysiological mechanisms underlying the association between type 2 diabetes mellitus and cardiovascular complications are complex and multifactorial. Chronic hyperglycemia, insulin resistance, dyslipidemia, oxidative stress, and low-grade systemic inflammation act synergistically to promote endothelial dysfunction, accelerate atherosclerotic plaque formation, and impair myocardial metabolism. These processes contribute to structural and functional alterations of the vascular wall, increased arterial stiffness, and adverse cardiac remodeling, ultimately leading to ischemic heart disease, hypertension, heart failure, and cerebrovascular disorders.

In addition to traditional cardiovascular risk factors, diabetes-specific mechanisms play a critical role in cardiovascular disease progression. Advanced glycation end products, activation of pro-inflammatory signaling pathways, and altered lipid metabolism further exacerbate vascular damage and impair adaptive responses of the cardiovascular system. As a result, patients with type 2 diabetes



Modern American Journal of Medical and Health Sciences

ISSN (E): 3067-803X

Volume 2, Issue 2, February 2026

Website: usajournals.org

This work is Licensed under CC BY 4.0 a Creative Commons Attribution 4.0 International License.

mellitus frequently present with diffuse and multivessel coronary artery disease, reduced collateral vessel formation, and diminished ischemic tolerance.

Despite advances in diagnostic and therapeutic approaches, the burden of cardiovascular complications in type 2 diabetes mellitus remains unacceptably high. This underscores the need for a comprehensive understanding of diabetes-related cardiovascular risk factors and pathogenic pathways. Early identification of subclinical cardiovascular alterations and timely implementation of preventive strategies are essential to reduce long-term morbidity and mortality.

The present study focuses on type 2 diabetes mellitus as a determinant factor in the development of cardiovascular complications. By analyzing key metabolic and pathophysiological mechanisms linking diabetes with cardiovascular disease, this research aims to contribute to improved risk stratification and support the development of integrated approaches for cardiovascular prevention in patients with type 2 diabetes mellitus.

Materials and Methods

The present study was designed as a clinical and analytical investigation aimed at evaluating the role of type 2 diabetes mellitus in the development of cardiovascular complications. The methodological framework combined clinical assessment, laboratory analysis, and statistical evaluation to identify diabetes-associated cardiovascular risk patterns.

The study population consisted of adult patients diagnosed with type 2 diabetes mellitus and a control group without diabetes, matched by age and sex. Inclusion criteria for the diabetic group included a confirmed diagnosis of type 2 diabetes mellitus based on established clinical guidelines and disease duration of at least five years. Exclusion criteria comprised acute cardiovascular events, severe renal or hepatic dysfunction, autoimmune diseases, and other endocrine disorders that could influence cardiovascular outcomes.

Clinical evaluation included anthropometric measurements, blood pressure assessment, and detailed medical history with particular emphasis on cardiovascular symptoms and comorbidities. Cardiovascular status was assessed using non-invasive diagnostic methods, including electrocardiography and



Modern American Journal of Medical and Health Sciences

ISSN (E): 3067-803X

Volume 2, Issue 2, February 2026

Website: usajournals.org

This work is Licensed under CC BY 4.0 a Creative Commons Attribution 4.0 International License.

echocardiography, to detect structural and functional cardiac abnormalities. Indicators of vascular involvement were evaluated through measurements of arterial stiffness and endothelial function.

Laboratory investigations were performed to characterize metabolic and cardiovascular risk profiles. Fasting plasma glucose, glycated hemoglobin, lipid profile parameters, and markers of systemic inflammation were analyzed using standardized biochemical methods. These indicators were selected to reflect chronic glycemic control, dyslipidemia, and inflammatory processes known to contribute to cardiovascular pathology in patients with type 2 diabetes mellitus. Cardiovascular complications were identified based on clinical records and instrumental findings and included ischemic heart disease, arterial hypertension, heart failure, and cerebrovascular disorders. The prevalence and distribution of these complications were analyzed in relation to metabolic control indicators and disease duration. The comparative characteristics of metabolic and cardiovascular parameters between diabetic and non-diabetic groups were summarized and later presented in tabular form in the Results section.

Statistical analysis was conducted using validated software packages. Quantitative variables were expressed as mean values with standard deviations, while qualitative variables were presented as frequencies and percentages. Group comparisons were performed using appropriate parametric or non-parametric tests depending on data distribution. Correlation and regression analyses were applied to evaluate associations between glycemic control parameters and cardiovascular outcomes. Statistical significance was defined at a p-value of less than 0.05.

The applied methodological approach ensured a comprehensive assessment of the relationship between type 2 diabetes mellitus and cardiovascular complications and provided a robust basis for subsequent quantitative analysis and interpretation of results.

Results

The comparative analysis demonstrated significant differences in metabolic and cardiovascular parameters between patients with type 2 diabetes mellitus and the



non-diabetic control group. Patients with type 2 diabetes showed markedly poorer glycemic control, adverse lipid profiles, and a higher prevalence of cardiovascular complications. The main clinical and laboratory characteristics of the study groups are summarized in **Table 1**.

Table 1. Clinical and laboratory characteristics of patients with type 2 diabetes mellitus and the control group

Parameter	Type 2 diabetes mellitus (n = 120)	Control group (n = 100)	p-value
Age (years)	58.4 ± 7.6	57.1 ± 6.9	>0.05
Disease duration (years)	8.9 ± 3.4	–	–
Fasting plasma glucose (mmol/L)	8.7 ± 1.9	5.1 ± 0.6	<0.001
HbA1c (%)	7.9 ± 1.2	5.3 ± 0.5	<0.001
Total cholesterol (mmol/L)	5.8 ± 1.1	4.6 ± 0.9	<0.01
LDL cholesterol (mmol/L)	3.6 ± 0.8	2.5 ± 0.6	<0.01
Systolic blood pressure (mmHg)	142 ± 18	126 ± 14	<0.01
Presence of cardiovascular complications (%)	62.5	28.0	<0.001

As shown in **Table 1**, patients with type 2 diabetes mellitus exhibited significantly higher fasting plasma glucose and glycated hemoglobin levels, indicating inadequate long-term glycemic control. In addition, diabetic patients demonstrated significantly elevated total and low-density lipoprotein cholesterol levels, reflecting an atherogenic lipid profile. Systolic blood pressure values were also markedly higher in the diabetic group, contributing to increased cardiovascular risk.

The prevalence of cardiovascular complications was substantially greater among patients with type 2 diabetes mellitus compared with the control group. Ischemic heart disease, arterial hypertension, and heart failure were the most frequently observed complications. The distribution of major cardiovascular complications in patients with type 2 diabetes mellitus is illustrated in **Figure 1**.





Figure 1. Prevalence of major cardiovascular complications in patients with type 2 diabetes mellitus

Figure 1 presents the distribution of major cardiovascular complications among patients with type 2 diabetes mellitus. Arterial hypertension was the most prevalent condition, followed by ischemic heart disease and heart failure. The



data demonstrate a high burden of cardiovascular pathology associated with long-term metabolic disturbances in type 2 diabetes.

Further analysis revealed a positive association between poor glycemic control and the occurrence of cardiovascular complications. Higher HbA1c levels were significantly correlated with increased prevalence of ischemic heart disease and heart failure. Patients with longer diabetes duration exhibited more frequent and severe cardiovascular manifestations, suggesting a cumulative effect of chronic metabolic dysregulation on cardiovascular structure and function.

Overall, the results confirm that type 2 diabetes mellitus is strongly associated with unfavorable metabolic profiles and a markedly increased risk of cardiovascular complications. These findings emphasize the central role of chronic hyperglycemia and associated metabolic abnormalities in accelerating cardiovascular disease development in diabetic patients.

Discussion

The findings of the present study confirm that type 2 diabetes mellitus is strongly associated with the development and progression of cardiovascular complications. As demonstrated in Table 1, patients with type 2 diabetes exhibited significantly poorer glycemic control, a more atherogenic lipid profile, and higher blood pressure levels compared with the non-diabetic control group. These metabolic abnormalities represent well-established cardiovascular risk factors and act synergistically to accelerate vascular damage and cardiac dysfunction in diabetic patients.

A notable observation of this study is the high prevalence of cardiovascular complications among patients with type 2 diabetes mellitus. As illustrated in Figure 1, arterial hypertension and ischemic heart disease were the most frequently observed conditions, followed by heart failure. This distribution is consistent with current pathophysiological concepts suggesting that chronic hyperglycemia and insulin resistance promote endothelial dysfunction, vascular inflammation, and atherosclerotic plaque formation, thereby increasing susceptibility to ischemic and hypertensive cardiovascular disorders.



Modern American Journal of Medical and Health Sciences

ISSN (E): 3067-803X

Volume 2, Issue 2, February 2026

Website: usajournals.org

This work is Licensed under CC BY 4.0 a Creative Commons Attribution 4.0 International License.

The significant association between elevated HbA1c levels and the presence of cardiovascular complications highlights the central role of long-term glycemic control in cardiovascular risk modulation. Chronic exposure to hyperglycemia leads to the formation of advanced glycation end products, activation of oxidative stress pathways, and impairment of nitric oxide bioavailability, all of which contribute to endothelial dysfunction and vascular stiffness. These mechanisms may explain the observed correlation between poor metabolic control and increased prevalence of ischemic heart disease and heart failure in the diabetic group.

Importantly, the results suggest that cardiovascular complications in type 2 diabetes mellitus often develop in parallel with metabolic disturbances rather than as isolated outcomes. Dyslipidemia, characterized by elevated total and low-density lipoprotein cholesterol levels, further exacerbates atherosclerotic processes and enhances plaque instability. When combined with elevated blood pressure, these factors substantially increase the risk of adverse cardiovascular events and worsen clinical prognosis.

Another relevant finding is the influence of disease duration on cardiovascular outcomes. Patients with longer-standing diabetes demonstrated a higher frequency of cardiovascular complications, supporting the concept of cumulative cardiovascular damage resulting from prolonged metabolic dysregulation. This underscores the importance of early diagnosis and timely intervention to prevent or delay the onset of cardiovascular pathology in patients with type 2 diabetes mellitus.

From a clinical and public health perspective, the present findings emphasize that effective management of type 2 diabetes mellitus should extend beyond glycemic control alone. Comprehensive cardiovascular risk reduction strategies, including aggressive management of blood pressure and lipid abnormalities, are essential to mitigate the high burden of cardiovascular disease in this population. The data also support the need for regular cardiovascular screening, even in asymptomatic diabetic patients, to enable early detection of subclinical cardiovascular changes. Overall, the study reinforces the concept that type 2 diabetes mellitus is a major determinant of cardiovascular complications and highlights the interconnected



nature of metabolic and cardiovascular dysfunction. Integrating metabolic control with targeted cardiovascular prevention strategies is crucial for reducing morbidity and mortality associated with type 2 diabetes mellitus.

Conclusion

The results of this study demonstrate that type 2 diabetes mellitus plays a decisive role in the development of cardiovascular complications and significantly increases cardiovascular risk compared with non-diabetic individuals. Patients with type 2 diabetes exhibited markedly poorer metabolic control, adverse lipid profiles, and elevated blood pressure levels, all of which contributed to a substantially higher prevalence of cardiovascular pathology.

The strong association between chronic hyperglycemia, as reflected by elevated HbA1c levels, and cardiovascular complications highlights the importance of long-term metabolic dysregulation in driving vascular and cardiac damage. The high prevalence of arterial hypertension, ischemic heart disease, and heart failure observed among diabetic patients confirms that cardiovascular involvement represents a major clinical burden in this population and often develops progressively with disease duration.

These findings indicate that glycemic control alone is insufficient to prevent cardiovascular complications in patients with type 2 diabetes mellitus. Comprehensive risk reduction strategies addressing dyslipidemia, hypertension, and other modifiable cardiovascular risk factors are essential to mitigate disease progression. Early identification of cardiovascular involvement and implementation of integrated preventive approaches may significantly reduce morbidity and improve long-term outcomes.

Overall, the study reinforces the concept of type 2 diabetes mellitus as a systemic metabolic disorder with profound cardiovascular implications and underscores the necessity of multidisciplinary management strategies aimed at reducing cardiovascular complications and improving patient prognosis.



References

1. American Diabetes Association. (2023). Cardiovascular disease and risk management: Standards of care in diabetes—2023. *Diabetes Care*, 46(Supplement 1), S158–S190. <https://doi.org/10.2337/dc23-S010>
2. Cosentino, F., Grant, P. J., Aboyans, V., et al. (2020). 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases. *European Heart Journal*, 41(2), 255–323. <https://doi.org/10.1093/eurheartj/ehz486>
3. Fox, C. S., Golden, S. H., Anderson, C., et al. (2015). Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus. *Circulation*, 132(8), 691–718. <https://doi.org/10.1161/CIR.0000000000000230>
4. Haffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998). Mortality from coronary heart disease in subjects with type 2 diabetes. *New England Journal of Medicine*, 339(4), 229–234. <https://doi.org/10.1056/NEJM199807233390404>
5. Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016). Clinical update: Cardiovascular disease in diabetes mellitus. *Circulation*, 133(24), 2459–2502. <https://doi.org/10.1161/CIRCULATIONAHA.116.022194>
6. Rawshani, A., Rawshani, A., Franzén, S., et al. (2018). Mortality and cardiovascular disease in type 2 diabetes. *New England Journal of Medicine*, 379(7), 633–644. <https://doi.org/10.1056/NEJMoa1800256>
7. Ташпулатова, Ф. К., Садыков, А. С., & Галиуллин, Т. И. (2017). МЕДИКО-СОЦИАЛЬНЫЕ АСПЕКТЫ ТУБЕРКУЛЕЗА ЛЕГКИХ И ВИЧ. *Фтизиатрия и пульмонология*, (2), 136-136.
8. Bekembayeva, G. S., & Tashpulatova, F. K. (2021). PROGNOSIS OF RESISTANT TUBERCULOSIS COURSE AMONG CHILDREN AND TEENAGERS. *Новый день в медицине*, (1), 48-51.
9. Khomova, N., Tashpulatova, F., & Sultanov, S. (2017). Compliance-is patient adherence to treatment, as well as partnerships between doctor and patient.
10. Ташпулатова, Ф. К., Галиуллин, Т. И., & Жумаев, О. А. (2018). АССОЦИАЦИЯ РИСКА РАЗВИТИЯ КАЗЕОЗНОЙ ПНЕВМОНИИ ПРИ ТУБЕРКУЛЕЗЕ ЛЕГКИХ С ГЕНЕТИЧЕСКИМИ МАРКЕРАМИ. *Интернаука*, (14-1), 52-53.



11. Вахабов, А. А., & Ташпулатова, Ф. К. (2018). Поражение печени у больных туберкулезом легких при побочных реакциях от противотуберкулезных препаратов. Молодой ученый, (3), 91-93.
12. Хомова, Н. А., Коломиец, В. М., & Ташпулатова, Ф. К. (2020). Приверженность к лечению больных туберкулезом как фактор риска снижения его эффективности. In Университетская наука: взгляд в будущее (pp. 314-319).
13. Tashpulatova, F., Shamshieva, N., Mukhteremova, V., Medvedeva, N., & Kurbanov, A. (2021). Phytotherapy in the Complex Treatment of Patients with Drug-Resistant Forms of Pulmonary Tuberculosis. Annals of the Romanian Society for Cell Biology, 25(1), 367-372.
14. Ташпулатова, Ф. К., Жалолов, А. Ж., Медведева, Н. В., & Долгушева, Ю. В. (2016). Уровень комплаенса у больных с лекарственно устойчивым туберкулезом. In Медицина: вызовы сегодняшнего дня (pp. 46-50).
15. Tashpulatova, F. K. (2003). Prevention of adverse reactions of antituberculous drugs in pulmonary tuberculosis in patients with different genetic background. Problemy tuberkuleza i boleznei legkikh, (6), 17-20.
16. Ташпулатова, Ф. К. (2017). Выявление туберкулеза легких в общесоматических лечебных учреждениях. Молодой ученый, (3), 236-238.
17. Ташпулатова, Ф. К., & Абдусаломова, М. И. (2020). Частота и характер побочных реакций от противотуберкулезных лекарственных средств у больных детей туберкулезом. Новый день в медицине, 2(30), 544-547.
18. Ташпулатова, Ф. К., & Абдусаломова, М. И. (2020). Частота и характер побочных реакций от противотуберкулезных лекарственных средств у больных детей туберкулезом. Новый день в медицине, 2(30), 544-547.
19. Isomov, M. M. (2020). Features of etiopathogenesis and the course of inflammatory processes of periapical tissues in women during pregnancy (review of literature)/Isomov MM, Shomurodov KE, Olimjonov KJ, Azimov IM. Biomedicine and practice.–2020.–№ SI-2, 833-838.
20. Isomov, M. M., Shomurodov, K. E., Olimjonov, K. J., & Azimov, I. M. (2020). Features of etiopathogenesis and the course of inflammatory



-
- processes of periapical tissues in women during pregnancy. *Journal Biomedicine and Practice*, 833-838.
21. Shomurodov, K. E., Kuryazova, Z. K., Isomov, M. M., Mukimov, I. I., & Fayziyev, B. R. (2017). Improvement of surgical treatment of fractures of the inferior orbit wall. *J Stomatologiya* 2017, 2, 78-80.
 22. Шомуродов, К. Э., & Исомов, М. М. (2020). Мониторинг стационарной и амбулаторной реабилитации беременных женщин с воспалительными заболеваниями ЧЛЮ. *Стоматология*, 1, 34-37.
 23. Shomurodov, K. E., & Isomov, M. M. (2021). Cytokine profile of blood plasma and oral fluid in pregnant women with odontogenic inflammatory diseases. *Central Asian Journal of Medical and Natural Science*, 2(3), 118-122.
 24. Исомов, М. М., Шомуродов, К. Э., & Ахмадалиев, Н. Н. (2020). Мониторинг госпитализированных беременных женщин с одонтогенными воспалительными заболеваниями ЧЛЮ за 2017-2019 гг. на базе клиники взрослой хирургической стоматологии ТГСИ. In *Инновационная стоматология* (pp. 116-119).
 25. Мусаев, Ш., Шомуродов, К., & Исомов, М. (2020). Частота и характеристика переломов нижней челюсти у детей. *Стоматология*, 1(1 (78)), 45-48.
 26. Шомуродов, К. Э., & Мирхусанова, Р. С. (2021). МРТ визуализация структур небно-глоточной области после уранопластики различными способами. In *Актуальные вопросы стоматологии детского возраста* (pp. 340-346).
 27. Шомуродов, К. Э., & Мирхусанова, Р. С. (2020). АНАТОМО-ФУНКЦИОНАЛЬНОЕ СОСТОЯНИЕ МЯГКОГО НЁБА И ЯЗЫЧКА ПОСЛЕ УРАНОПЛАСТИКИ У ДЕТЕЙ С ВРОЖДЁННОЙ РАСЩЕЛИНОЙ НЁБА. In *СОВРЕМЕННЫЕ АСПЕКТЫ КОМПЛЕКСНОЙ СТОМАТОЛОГИЧЕСКОЙ РЕАБИЛИТАЦИИ ПАЦИЕНТОВ С ДЕФЕКТАМИ ЧЕЛЮСТНО-ЛИЦЕВОЙ ОБЛАСТИ* (pp. 187-191).



-
28. Садикова, Х., Махкамов, Б., Абдувалиев, Н., Мамурбоева, М., & Исомов, М. (2019). Преимущества двухэтапной имплантации с применением пьезоинструментов для костного расщепления и аутогенной плазмы крови, обогащенной тромбоцитами. *Стоматология*, 1(1 (74)), 24-27.
 29. Шомуродов, К. Э., & Мирхусанова, Р. С. СРАВНИТЕЛЬНАЯ ОЦЕНКА СОСТОЯНИЯ НЕБНО-ГЛОТОЧНОГО КОЛЬЦА ПОСЛЕ УРАНОПЛАСТИКИ МЕТОДОМ МРТ. *ББК*, 56, 56.
 30. Искандарова, Ш. Т., Расулова, Н. Ф., Хасанова, М. И., & Юсупалиева, К. Б. (2019). Современные проблемы гигиены почвы в условиях Узбекистана почвы в условиях Узбекистана Ташкент:" Фан.
 31. Фахриев, Ж. А., Нозимова, Н. Х., & Расулова, Н. Ф. (2019). Сидячий образ жизни и его влияние на здоровье человека. *Теория и практика современной науки*, (3 (45)), 318-321.
 32. Расулова, Н. Ф. (2016). Совершенствование методов этического воспитания медицинских сестёр лечебно-профилактических учреждений. *Молодой ученый*, (7), 409-412.
 33. Rasulova, N. F., Jalilova, G. A., & Mukhamedova, N. S. (2023). PREVENTION OF IMPORTANT NON-COMMUNICABLE DISEASES AMONG THE POPULATION. *Евразийский журнал медицинских и естественных наук*, 3(1 Part 2), 2123.
 34. Nazarova, S. K., Jalilova, G. A., Mukhamedova, N. S., & Rasulova, N. F. (2021). Features of distance learning organization. *Annals of the Romanian Society for Cell Biology*, 25(1), 339-347.
 35. Усманов, И. А., Джалилова, Г. А., & Расулова, Н. Ф. (2016). К вопросу охраны водных объектов бассейна Амударьи на примере Кашкадарьинской области. *Вестник науки и образования*, (2 (14)), 95-98.
 36. Мирзаева, М. А., & Расулова, Н. Ф. (2014). Компьютеризация рабочего места медицинских сестер стационара. *Сборник статей и тезисов*.
 37. Расулова, Н. Ф. (2011). Ўзбекистонда педиатриянинг ривожланиш тарихи.



-
38. Rasulova, N., Abdullaev, K., & Kuddusova, K. (2024). THE INTEGRATED APPROACH TO THE TREATMENT OF PATIENTS WITH ATROPHIC RHINITIS WHO HAVE COVID-19. *Science and innovation*, 3(D7), 56-60.
39. Расулова, Н. Ф., & Асадова, Г. А. (2023). ИЗУЧЕНИЕ ОСОБЕННОСТИ ЗДОРОВЬЕСОХРАНЯЮЩЕГО ПОВЕДЕНИЯ И САМООЦЕНКА ЗДОРОВЬЯ СТУДЕНТОВ. *Science and innovation*, 2(Special Issue 8), 978-980.
40. Sarwar, N., Gao, P., Seshasai, S. R. K., et al. (2010). Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease. *The Lancet*, 375(9733), 2215–2222. [https://doi.org/10.1016/S0140-6736\(10\)60484-9](https://doi.org/10.1016/S0140-6736(10)60484-9)
41. Seferović, P. M., Petrie, M. C., Filippatos, G. S., et al. (2018). Type 2 diabetes mellitus and heart failure. *European Journal of Heart Failure*, 20(5), 853–872. <https://doi.org/10.1002/ejhf.1170>
42. Stratton, I. M., Adler, A. I., Neil, H. A. W., et al. (2000). Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes. *BMJ*, 321(7258), 405–412. <https://doi.org/10.1136/bmj.321.7258.405>
43. Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001). Global and societal implications of the diabetes epidemic. *Nature*, 414(6865), 782–787. <https://doi.org/10.1038/414782a>